{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055654","form_type":"8-K","ticker":null,"cik":"0001496323","company_name":"IGM Biosciences, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.664541+00:00","generated_at":"2026-06-02T09:44:08.471357+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Q1 net loss narrows to $49.8M; aplitabart colorectal trial enrollment exceeds target","bullets":["Net loss $49.8M ($0.83/share) vs $59.3M ($1.33/share) in Q1 2023; operating expenses decreased.","Cash and investments $293.8M at March 31, 2024, down from $337.7M at Dec 31, 2023.","Aplitabart randomized colorectal trial enrollment exceeded target of 110 patients, now over 120; top-line PFS data expected by Q1 2025.","Imvotamab completed first dose cohort in rheumatoid arthritis (6 active, 2 placebo); two higher-dose cohorts planned.","FY 2024 guidance: GAAP OpEx $210-220M; collaboration rev ~$63M (mostly Q2); cash runway into Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055654","json":"https://secwatch.observer/filing/0000950170-24-055654.json","markdown":"https://secwatch.observer/filing/0000950170-24-055654.md","text":"https://secwatch.observer/filing/0000950170-24-055654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/0000950170-24-055654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/igms-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:44:08.471357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7fa29243ed7170562170bb03cf2b0481229f9045","claim":"IGM Biosciences, Inc. reported the fiscal quarter ended March 31, 2024 results: net income $49.8 million, or a loss of $0.83 per share, EPS $0.83 per share.","evidence_excerpt":"For the first quarter of 2024, net loss was $49.8 million, or a loss of $0.83 per share, compared to a net loss of $59.3 million, or a loss of $1.33 per share, for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/0000950170-24-055654-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2024"},{"label":"Net income","value":"$49.8 million, or a loss of $0.83 per share"},{"label":"EPS","value":"$0.83 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}